As part of the confirmatory stage of phase III, the U.S. Food and Drug Administration (FDA) has given Onconase orphan and fast-track drug status. This designation allows Alfacell (the company running the clinical trial) to be awarded seven years of marketing the drug for treatment of malign...
Chemotherapy is a standard mesothelioma treatment. Learn how it can be part of a multimodal approach to managing mesothelioma and improving survival.
This review of malignant mesothelioma focuses on the activity of single-agent and combination chemotherapy, a field in which research has thus far been rather unsystematic and sparse. Available results neither accede to any substantial drug activity nor justify the use of standard therapy. Furthermore...
According to published studies, ovarian clear cell adenocarcinomas (OCCAs) account for less than 5 percent of all ovarian malignancies, and 3.7–12.1 percent of all epithelial ovarian carcinomas. By contrast, early‐stage clear cell ovarian cancer carries a relatively good prognosis. When compared wi...
The activity of single-agent irinotecan (125 mg m−2given weekly for 4 weeks, every 6 weeks) in malignant mesothelioma was investigated by the CALGB (Kindler et al, 2000). In 28 patients evaluable for analysis, no complete or partial responses were observed and the median overall survi...
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations. Centers for Disease Control and Prevention. (2023, November 1). Diabetes. Retrieved fromhttps://www.cd...
PFSbydiseasestage(IIIA/IIIB/IIIC) Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse. PFSbyresponsetoneoadjuvanttherapy Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse. OSwithNIVOConsolidationvsObservation ...
Introduction: Trimodality therapy (including surgery, chemotherapy and radiation therapy) represents an important management approach of early-stage malignant pleural mesothelioma (MPM). The oncological value, as well as the proper sequence of the three modalities, is still under investigations. Areas ...
The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future